A team of Jacobs School of Medicine and Biomedical Sciences researchers has published a paper that provides novel guidelines for clinicians when discussing brain atrophy with their multiple sclerosis (MS) patients.
Fifteen faculty members and three staff members from the Jacobs School of Medicine and Biomedical Sciences were among those honored for notable achievements and service at the 19th annual University at Buffalo Celebration of Faculty and Staff Academic Excellence.
Peter L. Elkin, MD, UB Distinguished Professor and chair of biomedical informatics at the Jacobs School of Medicine and Biomedical Sciences, has been awarded an R25 grant from the National Institutes of Health’s National Library of Medicine (NLM) to train underrepresented minorities in biomedical informatics and data science.
Multiple sclerosis (MS) patients may be better equipped to stave off the cognitive decline that the disease can cause by using a smartphone-based app now under development at the Jacobs School of Medicine and Biomedical Sciences.
Peter L. Elkin, MD, UB Distinguished Professor and chair of biomedical informatics at the Jacobs School of Medicine and Biomedical Informatics, has received two prestigious honors.
Nineteen faculty members with clinical and research experience have joined the departments of Biomedical Informatics, Family Medicine, Medicine, Orthopaedics, Pathology and Anatomical Sciences, Pediatrics, Physiology and Biophysics, and Psychiatry.
The Jacobs School of Medicine and Biomedical Sciences hosted the 2022 National Library of Medicine (NLM) T15 Informatics Training Conference June 22-24.
Seven of the 20 UB faculty and staff members who have been named recipients of the 2022 SUNY Chancellor’s Award for Excellence have connections to the Jacobs School of Medicine and Biomedical Sciences.
Twenty-eight doctoral, 62 master’s and 205 baccalaureate candidates were eligible to receive degrees in biomedical science fields during the May commencement ceremony.
Patients hospitalized with COVID-19 pneumonia had a 13.5% survival advantage when treated with a combination of leukotriene inhibitors (LTIs) and the steroid dexamethasone.
